CraigCHofmeisterMD

Oncology • Atlanta, GA

Hematologic Oncology

Associate Professor, Winship Cancer Institute, Emory University

Join to view full profile

Dr. Hofmeister is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hofmeister's full profile

Already have an account?

Office
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 404-778-8580

Fax+1 404-778-1215

Summary

I am a hematologist specializing in patients with multiple myeloma.

Education & Training

Ohio State UniversityMPH, Clinical Investigation, 2009 - 2012
Loyola University Medical CenterFellowship, Hematopoietic Stem Cell Transplantation, 2005 - 2006
Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2002
Ohio State University College of MedicineClass of 1999
Brown UniversityBS, Biochemistry and Molecular Biology, 1991 - 1995

Certifications & Licensure

GA State Medical License 2017 - 2025
LA State Medical License 2020 - 2022
NC State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
OH State Medical License 2006 - 2018
IL State Medical License 1999 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Business First’s Forty Under 40 Award Columbus Dispatch, 2011
Early Career Achievement Award The Ohio State University College of Medicine, 2011
Imagine MMORE Award MMORE (Multiple Myeloma Opportunities for Research & Education), 2009
Internal Medicine Senior Resident of the Year Award 2002
Samuel J. Roessler Research Scholarship The Ohio State College of Medicine, 1996
Join now to see all

Clinical Trials

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma Start of enrollment: 2004 Jul 01
Completed
Phase 2
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease Start of enrollment: 2003 Jul 01
Completed
Phase 2
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation Start of enrollment: 2004 Feb 01
Completed
Phase 2
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma Start of enrollment: 2007 Mar 01
Completed
Phase 1
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma Start of enrollment: 2007 Dec 12
Completed
Not Applicable
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2008 Sep 26
Completed
Phase 1
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01
Completed
Phase 1, Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Start of enrollment: 2010 May 04
Completed
Phase 1
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource Start of enrollment: 2011 Mar 17
Recruiting
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 Apr 01
Completed
Phase 1
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Comprehensive Frailty Assessment Start of enrollment: 2014 Apr 01
Completed
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Dec 09
Completed
Phase 1
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 1, Phase 2
Daratumumab in Treating Patients With Multiple Myeloma Start of enrollment: 2017 Feb 22
Completed
Phase 2
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant Start of enrollment: 2018 Sep 01
Withdrawn
Phase 2
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma Start of enrollment: 2018 Oct 24
Completed
Phase 1
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders Start of enrollment: 2019 Oct 18
Completed
Phase 4
Personalized Autologous Transplant for Multiple Myeloma Start of enrollment: 2021 May 20
Recruiting
Phase 1
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis Start of enrollment: 2021 Apr 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

633 citations
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Don M. Benson, Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne A. Efebera
Blood. 2010-09-30
298 citations
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz
Blood. 2014-03-20
51 citations
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, Nizar J. Bahlis, Dan T. Vogl
Leukemia. 2020-02-24

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply
Hofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
Evaluation of pulmonary infiltrates in post stem cell transplant patients
Scaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
Mucosal protection by cytokines
Hofmeister CC, Stiff PJ, Current Hematology Reports, 11/1/2005
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmeister CC, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kueh..., Cancer Cell
Join now to see all

Abstracts/Posters

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

When Is Treating a Precursor Condition Harmful?October 8th, 2024
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual MeetingMay 29th, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational HighlightsMarch 5th, 2020
Join now to see all